Altogether, these results encourage implication of ATX-LPAR1 combination therapy or dual inhibitors of ATX-LPAR1 as treatment for various cancers, IPF and rheumatoid arthritis. Here, LPAR1 is linked to idiopathic pulmonary fibrosis.